Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.70 |
| ▸ | SRC | P12931 | 3/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030886 | 0.94 | EGFR (0.63) | EGFRERBB2SRCKCNH2EPHA2 | |
| SCHEMBL4036090 | 0.89 | EGFR (0.77) | EGFRERBB2SRCKCNH2 | |
| SCHEMBL4033944 | 0.87 | EGFR (0.80) | EGFRERBB2SRCKCNH2EPHA2 | |
| Hydrochloric Acid SCHEMBL4028717 | 0.86 | EGFR (0.79) | EGFRERBB2SRCKCNH2EPHA2 | |
| SCHEMBL4034391 | 0.83 | EGFR (0.75) | EGFRERBB2SRC | |
| SCHEMBL5478362 | 0.82 | ERBB2 (1.00) | EGFRERBB2KCNH2 | |
| SCHEMBL4034279 | 0.82 | EGFR (0.80) | EGFRERBB2SRCKCNH2 | |
| SCHEMBL4034510 | 0.81 | EGFR (0.77) | EGFRERBB2SRCKCNH2EPHA2 | |
| SCHEMBL4031328 | 0.81 | EGFR (0.82) | EGFRERBB2SRCKCNH2 | |
| SCHEMBL4030822 | 0.80 | EGFR (0.69) | EGFRERBB2SRCKCNH2EPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444210-B1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-12 | — | — | US | disclosed |
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | US | disclosed |
| EP-1444210-A1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040108-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | EGFR 4/4885ERBB2 1/4885SRC 111/4885 |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885SRC 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.